drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Humanized anti-HER2 monoclonal antibody; in this trial delivered intrathecally to bind HER2, block receptor signaling, and mediate ADCC within the CSF.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intrathecal
drug_mechanism_of_action
Humanized anti-HER2 (ERBB2) monoclonal antibody that binds HER2 on tumor cells, blocks receptor signaling and downstream proliferative pathways, and induces Fc-mediated ADCC; here administered intrathecally to act within the CSF against leptomeningeal disease.
drug_name
Trastuzumab
nct_id_drug_ref
NCT05800275